We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Enfortumab Vedotin Is Effective in Patients With Aggressive Bladder Cancer

Enfortumab Vedotin Is Effective in Patients With Aggressive Bladder Cancer

Enfortumab Vedotin Is Effective in Patients With Aggressive Bladder Cancer

Enfortumab Vedotin Is Effective in Patients With Aggressive Bladder Cancer

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Enfortumab Vedotin Is Effective in Patients With Aggressive Bladder Cancer"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Findings from a new study led by Yale Cancer Center researchers show enfortumab vedotin is effective in patients with muscle-invasive bladder cancer (MIBC) not eligible for cisplatin chemotherapy. The data is from Cohort H of the Phase 1/b2 EV-103 clinical trial being presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (ASCO GU) on February 18, 2022.

Our findings showed more than one-third of patients displayed no evidence of cancer when their bladder was removed after receiving enfortumab vedotin prior to surgery,” said Daniel P. Petrylak, MD, Professor of Medicine (Medical Oncology) and Urology and Co-Director of the Cancer Signaling Research Program at Yale Cancer Center, and principal investigator for the study. “The results are significant and so encouraging as survival rates are poor for muscle-invasive bladder cancer.”

MIBC is a type of bladder cancer where the tumor has spread into the muscle of the bladder wall and more likely to spread to other parts of the body. 25% of bladder cancers are diagnosed as MIBC. Treatment for MIBC typically combines cisplatin-based chemotherapy with surgery.

In this trial, researchers enrolled patients diagnosed with MIBC, ineligible for cisplatin-based chemotherapy, but eligible for surgical treatment. Patients received three cycles of neoadjuvant (prior to surgery) enfortumab vedotin, an anti-body drug, on days one and eight of every three-week cycle. Results from the preliminary analysis of 22 patients showed 36.4 percent had a pathologic complete response, the primary endpoint, displaying no signs of cancer upon microscopic examination of tissue cells removed during surgery. Half of the patients had a pathological downstaging, or reduction in tumor size. All patients underwent surgery, and there were no surgeries delayed due to treatment from enfortumab vedotin.

Petrylak added, “We look forward to phase 3 studies to further evaluate the effectiveness of enfortumab vedotin.”

Funding for this study was provided by Astellas, a multinational pharmaceutical company, and Seagen, an American biotechnology company.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.